Clear Cell News Today

David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

The Children's Cancer Therapy Development Institute (cc-TDI), proudly announces a global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports.

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.

Expert oncologists who treat patients with advanced RCC discuss updates from clinical trials presented during the 2023 European Society for Medical Oncology Congress that further defined the treatment paradigm in advanced RCC and gave a peek into the potential future of the disease management.

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] This call is being recorded and will be available on the investors section of the ARCUS website. I will now […]

Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions.

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.